Patents Assigned to Sera Prognostics, Inc.
-
Patent number: 11987846Abstract: The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female.Type: GrantFiled: March 1, 2021Date of Patent: May 21, 2024Assignee: Sera Prognostics, Inc.Inventors: John Jay Boniface, Andrew Gassman, Jeff Flick, Chad Bradford, Ashoka Polpitiya, Tracey Cristine Fleischer, Durlin Edward Hickok, Paul Kearney, Gregory Charles Critchfield
-
Patent number: 11662351Abstract: Compositions and methods for predicting due date and time to birth for a pregnancy with significantly higher accuracy than current clinical methods. The compositions and methods for predicting due date and time to birth for a pregnancy can also identify those pregnancies that will deliver earlier than the due date derived from Last Menstrual Period (LMP) and/or obstetric ultrasonography (US) dating.Type: GrantFiled: August 17, 2018Date of Patent: May 30, 2023Assignee: Sera Prognostics, Inc.Inventors: John Jay Boniface, Paul Edward Kearney, Julja Burchard, Gregory Charles Critchfield, Durlin Edward Hickok, Tracey Cristine Fleischer, Ashoka Dharmapriya Polpitiya
-
Patent number: 10392665Abstract: The disclosure provides a pair of isolated biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1, wherein the pair of biomarkers exhibits a change in reversal value between pregnant females at risk for pre-term birth and term controls. Also provided is a method of determining probability for preterm birth in a pregnant female, the method comprising measuring in a biological sample obtained from the pregnant female a reversal value for at least one pair of biomarkers selected from the group consisting of IBP4/SHBG, IBP4/PSG3, IBP4/LYAM1, IBP4/IGF2, CLUS/IBP3, CLUS/IGF2, CLUS/LYAM1, INHBC/PSG3, INHBC/IGF2, PSG2/LYAM1, PSG2/IGF2, PSG2/LYAM1, PEDF/PSG3, PEDF/SHBG, PEDF/LYAM1, CD14/LYAM1, and APOC3/LYAM1 to determine the probability for preterm birth in the pregnant female.Type: GrantFiled: June 17, 2016Date of Patent: August 27, 2019Assignee: Sera Prognostics, Inc.Inventors: John Jay Boniface, Andrew Gassman, Jeff Flick, Chad Bradford, Ashoka Polpitiya, Tracey Cristine Fleischer, Durlin Edward Hickok, Paul Kearney, Gregory Charles Critchfield
-
Publication number: 20140287948Abstract: The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexepected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Applicant: Sera Prognostics, Inc.Inventors: John Jay BONIFACE, Gregory Charles CRITCHFIELD, Durlin Edward HICKOK
-
Publication number: 20140287950Abstract: The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexepected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Applicant: Sera Prognostics, Inc.Inventors: Durlin Edward HICKOK, John Jay BONIFACE, Gregory Charles CRITCHFIELD, Tracey Cristine FLEISCHER
-
Publication number: 20140287947Abstract: The disclosure provides biomarker panels, methods and kits for determining the probability for preeclampsia in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preeclampsia relative to matched controls. The present disclosure is further based, in part, on the unexepected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preeclampsia in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides dislosed herein serve as biomarkers for classifying test samples, predicting a probability of preeclampsia, monitoring of progress of preeclampsia in a pregnant female, either individually or in a panel of biomarkers.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Applicant: Sera Prognostics, Inc.Inventors: John Jay BONIFACE, Gregory Charles CRITCHFIELD, Durlin Edward HICKOK